Global quantitative phosphoproteome analysis of human tumor xenografts treated with a CD44 antagonist.

Weigand, Stefan; Herting, Frank; Maisel, Daniela; Nopora, Adam; Voss, Edgar; Schaab, Christoph; Klammer, Martin; Tebbe, Andreas

Weigand, Stefan; Herting, Frank; Maisel, Daniela; Nopora, Adam; Voss, Edgar; Schaab, Christoph; Klammer, Martin; Tebbe, Andreas.

Affiliation

Weigand S; Discovery Oncology, Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany. Stefan.weigand@roche.com

Cancer Res ; 72(17): 4329-39, 2012 Sep 01.

Article in En | MEDLINE | ID: mdl-22777824

Subject(s)

Antibodies, Monoclonal, Humanized/pharmacology; Antibodies, Monoclonal/pharmacology; Antineoplastic Agents/pharmacology; Hyaluronan Receptors/metabolism; Neoplasms/metabolism; Phosphoproteins/metabolism; Proteome/metabolism; Animals; Antibodies, Monoclonal/administration & dosage; Antibodies, Monoclonal, Humanized/administration & dosage; Antineoplastic Agents/administration & dosage; Computational Biology/methods; Female; Humans; MAP Kinase Signaling System/drug effects; Mice; Mice, SCID; Neoplasms/drug therapy; Proteomics; Xenograft Model Antitumor Assays

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phosphoproteins / Hyaluronan Receptors / Proteome / Antibodies, Monoclonal, Humanized / Antibodies, Monoclonal / Neoplasms / Antineoplastic Agents Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Cancer Res Year: 2012 Document type: Article Affiliation country: Germany

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google